💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling business — but flagged on governance.
Panacea Biotec is scored on the pharma / healthcare framework. It keeps a thin -1.1% of every rupee of sales as net profit. Free cash flow is worth about -1.1% of its market value.
Book value has been broadly flat (-0.4%/yr). Return on equity is a weak -2.9%.
It trades at -237× earnings. The forensic screen raises a red flag: Share count up 31% over 4 years — heavy equity dilution.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | -236.95 | — | — |
| P/B | 2.61 | 4.11 | better |
| EV/EBITDA | 74.3 | 19.15 | worse |
| ROE | -2.93 | 0.68 | worse |
| ROCE | -2.42 | 6.87 | worse |
| ROA | -0.71 | 1.26 | worse |
| Quick Ratio | 0.92 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
9% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
4 of the 4 years shown had a loss — profitability is inconsistent.
Operating margin has compressed from 3% to -1% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line. Margins have declined for 2 consecutive years — watch for a structural cost problem.
Negative ROE — the business is destroying shareholder value. Low variance across years — a predictable business that earns steadily on its equity base.
3 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 20% sequentially — momentum is building. Run-rate stepping up — recent quarters average 18% above earlier ones.
2 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 320% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (-9% → 1%) — profitability per rupee of revenue is improving.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoters hold 72.5% — heavily owner-operated with strong skin in the game. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.